paragon 28 was established in 2010 as an orthopedic foot and ankle company. the name “paragon 28” was chosen to show that we are exclusively a foot and ankle company, with the “28” representing the number of bones in the foot. we will remain true to that vision. paragon 28 was started as a small, family-based company and we have kept those core ideals as we have grown. our mission is to strategically build a company around the core principles that drive innovation and quality. relentlessly working to advance the science behind foot and ankle surgery, paragon 28 is passionate about and committed to: - creation and innovation: blending different surgical philosophies from various global thought leaders to develop bio-mechanically and clinically relevant surgical solutions. - a focus on service: a customer service based, dedicated, and highly trained distribution network to the foot and ankle market. - efficient practices: meeting the needs of increasing pricing pressures and reimbursemen
Company profile
Ticker
FNA
Exchange
Website
CEO
Albert DaCosta
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
OF PARAGON 28, INC. • Paragon 28 Australia • 1100% owned by Paragon 28, Inc. • 2 100% owned by Paragon 28 Medical Devices Trading Limited ...
IRS number
273170186
FNA stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
1 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Paragon 28 Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 24
8-K
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023
8 Jan 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Paragon 28 Announces New $150 Million Credit Facility Replacing Existing $90 Million Credit Facility
7 Nov 23
8-K
Paragon 28 Reports Third Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance
7 Nov 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Paragon 28 Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance
2 Aug 23
8-K
Departure of Directors or Certain Officers
19 May 23
Transcripts
FNA
Earnings call transcript
2023 Q3
7 Nov 23
FNA
Earnings call transcript
2023 Q2
3 Aug 23
FNA
Earnings call transcript
2023 Q1
4 May 23
FNA
Earnings call transcript
2022 Q4
2 Mar 23
FNA
Earnings call transcript
2022 Q3
10 Nov 22
FNA
Earnings call transcript
2022 Q2
6 Aug 22
FNA
Earnings call transcript
2022 Q1
10 May 22
FNA
Earnings call transcript
2021 Q4
9 Mar 22
FNA
Earnings call transcript
2021 Q3
22 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 34.95 mm | 34.95 mm | 34.95 mm | 34.95 mm | 34.95 mm | 34.95 mm |
Cash burn (monthly) | 7.27 mm | 1.78 mm | 2.99 mm | 5.66 mm | 4.70 mm | 5.06 mm |
Cash used (since last report) | 43.35 mm | 10.63 mm | 17.86 mm | 33.74 mm | 28.07 mm | 30.20 mm |
Cash remaining | -8.40 mm | 24.32 mm | 17.09 mm | 1.21 mm | 6.88 mm | 4.75 mm |
Runway (months of cash) | -1.2 | 13.7 | 5.7 | 0.2 | 1.5 | 0.9 |
Institutional ownership, Q3 2023
81.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 97 |
Opened positions | 9 |
Closed positions | 19 |
Increased positions | 33 |
Reduced positions | 31 |
13F shares | Current |
---|---|
Total value | 345.52 bn |
Total shares | 67.24 mm |
Total puts | 4.60 k |
Total calls | 9.00 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Bird B. | 15.55 mm | $275.10 mm |
MVM Partners | 14.41 mm | $281.37 mm |
Rosenthal Investment | 7.21 mm | $0.00 |
Braidwell | 3.36 mm | $42.19 bn |
BLK Blackrock | 3.35 mm | $42.02 bn |
First Light Asset Management | 2.74 mm | $34.36 bn |
Vanguard | 2.00 mm | $25.12 bn |
Bleichroeder | 1.76 mm | $22.13 bn |
Greenhouse Funds LLLP | 1.64 mm | $20.58 bn |
Loomis Sayles & Co L P | 1.58 mm | $19.89 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Albert DaCosta | Common Stock | Buy | Acquire P | Yes | No | 9.1152 | 28,000 | 255.23 k | 5,339,110 |
8 Mar 24 | Erik E Mickelson | Common Stock | Grant | Acquire A | No | No | 0 | 15,455 | 0.00 | 37,988 |
8 Mar 24 | Stephen Deitsch | Common Stock | Grant | Acquire A | No | No | 0 | 108,346 | 0.00 | 218,619 |
8 Mar 24 | Albert DaCosta | Common Stock | Grant | Acquire A | No | No | 0 | 166,924 | 0.00 | 643,336 |
News
Paragon 28 Adds To Suite Of Novel Syndesmosis Repair Solutions With Launch Of Grappler R3INFORCE Extraosseous Repair System
28 Mar 24
Needham Reiterates Buy on Paragon 28, Maintains $17 Price Target
28 Mar 24
Around $9M Bet On Cardlytics? Check Out These 4 Stocks Insiders Are Buying
19 Mar 24
Needham Maintains Buy on Paragon 28, Raises Price Target to $17
1 Mar 24
Earnings Scheduled For February 29, 2024
29 Feb 24
Press releases
Paragon 28 to Present at the CG 2024 Musculoskeletal Conference
12 Feb 24
Paragon 28 To Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
6 Feb 24
Paragon 28 Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures
30 Jan 24
Paragon 28 Launches the Mister Tendon™ Harvester System – The First and Only Minimally Invasive Harvesting System for FHL and FDL Tendon Transfer Procedures
26 Jan 24
Paragon 28 Announces First Cases and Limited Market Release of the Bun-Yo-Matic™ – A Next Generation Clamp and Cut Guide System for Lapidus Bunion Procedures
17 Jan 24